WO2023090903A1 - 신규 류코노스톡 메센테로이데스 균주를 포함하는 암 또는 염증 예방 또는 치료용 조성물 및 이를 이용한 암 또는 염증의 예방 또는 치료 방법 - Google Patents
신규 류코노스톡 메센테로이데스 균주를 포함하는 암 또는 염증 예방 또는 치료용 조성물 및 이를 이용한 암 또는 염증의 예방 또는 치료 방법 Download PDFInfo
- Publication number
- WO2023090903A1 WO2023090903A1 PCT/KR2022/018223 KR2022018223W WO2023090903A1 WO 2023090903 A1 WO2023090903 A1 WO 2023090903A1 KR 2022018223 W KR2022018223 W KR 2022018223W WO 2023090903 A1 WO2023090903 A1 WO 2023090903A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cjrs
- leuconostoc mesenteroides
- cancer
- accession
- composition
- Prior art date
Links
- 241000192130 Leuconostoc mesenteroides Species 0.000 title claims abstract description 68
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 61
- 239000000203 mixture Substances 0.000 title claims abstract description 61
- 201000011510 cancer Diseases 0.000 title claims abstract description 46
- 206010061218 Inflammation Diseases 0.000 title claims abstract description 18
- 230000004054 inflammatory process Effects 0.000 title claims abstract description 18
- 238000000034 method Methods 0.000 title claims description 17
- 210000004027 cell Anatomy 0.000 claims description 73
- 239000004480 active ingredient Substances 0.000 claims description 39
- 239000008194 pharmaceutical composition Substances 0.000 claims description 35
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 27
- 201000005202 lung cancer Diseases 0.000 claims description 27
- 208000020816 lung neoplasm Diseases 0.000 claims description 27
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 26
- 239000002246 antineoplastic agent Substances 0.000 claims description 24
- 206010006187 Breast cancer Diseases 0.000 claims description 22
- 208000026310 Breast neoplasm Diseases 0.000 claims description 22
- 206010009944 Colon cancer Diseases 0.000 claims description 20
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 16
- 230000002708 enhancing effect Effects 0.000 claims description 16
- 235000013305 food Nutrition 0.000 claims description 16
- 238000002626 targeted therapy Methods 0.000 claims description 15
- 230000036541 health Effects 0.000 claims description 14
- 230000036039 immunity Effects 0.000 claims description 13
- 238000011282 treatment Methods 0.000 claims description 13
- 235000013376 functional food Nutrition 0.000 claims description 12
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims description 6
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims description 6
- 238000011319 anticancer therapy Methods 0.000 claims description 5
- 230000002265 prevention Effects 0.000 claims description 5
- 108090000623 proteins and genes Proteins 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 239000003112 inhibitor Substances 0.000 claims description 4
- 230000003993 interaction Effects 0.000 claims description 4
- 230000004069 differentiation Effects 0.000 claims description 3
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 claims description 2
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 claims description 2
- 108060003951 Immunoglobulin Proteins 0.000 claims description 2
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 claims description 2
- 102100020862 Lymphocyte activation gene 3 protein Human genes 0.000 claims description 2
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims description 2
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 2
- 238000002512 chemotherapy Methods 0.000 claims description 2
- 102000018358 immunoglobulin Human genes 0.000 claims description 2
- 239000003446 ligand Substances 0.000 claims description 2
- 238000009099 neoadjuvant therapy Methods 0.000 claims description 2
- 238000002428 photodynamic therapy Methods 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 claims description 2
- 238000001959 radiotherapy Methods 0.000 claims description 2
- 239000004615 ingredient Substances 0.000 abstract description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 26
- 230000028327 secretion Effects 0.000 description 24
- 239000003814 drug Substances 0.000 description 21
- 230000000694 effects Effects 0.000 description 21
- 238000012790 confirmation Methods 0.000 description 17
- 229940079593 drug Drugs 0.000 description 17
- 239000002609 medium Substances 0.000 description 17
- 101000894590 Homo sapiens Uncharacterized protein C20orf85 Proteins 0.000 description 16
- 102100021442 Uncharacterized protein C20orf85 Human genes 0.000 description 16
- 238000010586 diagram Methods 0.000 description 16
- 210000004988 splenocyte Anatomy 0.000 description 15
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 14
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 14
- 239000002953 phosphate buffered saline Substances 0.000 description 14
- 241001465754 Metazoa Species 0.000 description 13
- 239000003674 animal food additive Substances 0.000 description 13
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 12
- 241000894006 Bacteria Species 0.000 description 11
- 230000001965 increasing effect Effects 0.000 description 11
- 210000002865 immune cell Anatomy 0.000 description 10
- 210000004985 myeloid-derived suppressor cell Anatomy 0.000 description 10
- 239000003242 anti bacterial agent Substances 0.000 description 9
- 230000001093 anti-cancer Effects 0.000 description 9
- 229940088710 antibiotic agent Drugs 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 238000009472 formulation Methods 0.000 description 9
- 241000192132 Leuconostoc Species 0.000 description 8
- 239000002253 acid Substances 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 108010034798 CDC2 Protein Kinase Proteins 0.000 description 7
- 102000008178 Cyclin B1 Human genes 0.000 description 7
- 108010060385 Cyclin B1 Proteins 0.000 description 7
- 102100032857 Cyclin-dependent kinase 1 Human genes 0.000 description 7
- 230000003115 biocidal effect Effects 0.000 description 7
- 238000003501 co-culture Methods 0.000 description 7
- 210000005008 immunosuppressive cell Anatomy 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 102000004127 Cytokines Human genes 0.000 description 6
- 108090000695 Cytokines Proteins 0.000 description 6
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 230000014509 gene expression Effects 0.000 description 6
- 239000004310 lactic acid Substances 0.000 description 6
- 235000014655 lactic acid Nutrition 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 239000003550 marker Substances 0.000 description 6
- 235000013336 milk Nutrition 0.000 description 6
- 239000008267 milk Substances 0.000 description 6
- 210000004080 milk Anatomy 0.000 description 6
- 235000012149 noodles Nutrition 0.000 description 6
- 239000003755 preservative agent Substances 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 102000006995 beta-Glucosidase Human genes 0.000 description 5
- 108010047754 beta-Glucosidase Proteins 0.000 description 5
- 230000025084 cell cycle arrest Effects 0.000 description 5
- 238000011284 combination treatment Methods 0.000 description 5
- 239000003937 drug carrier Substances 0.000 description 5
- 229940088598 enzyme Drugs 0.000 description 5
- 235000013373 food additive Nutrition 0.000 description 5
- 239000002778 food additive Substances 0.000 description 5
- 230000000968 intestinal effect Effects 0.000 description 5
- 210000002540 macrophage Anatomy 0.000 description 5
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 5
- 239000013642 negative control Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- 230000000638 stimulation Effects 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- WWSJZGAPAVMETJ-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-3-ethoxypyrazol-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C(=NN(C=1)CC(=O)N1CC2=C(CC1)NN=N2)OCC WWSJZGAPAVMETJ-UHFFFAOYSA-N 0.000 description 4
- 241000251468 Actinopterygii Species 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 235000010469 Glycine max Nutrition 0.000 description 4
- 244000068988 Glycine max Species 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 description 4
- 102100022338 Integrin alpha-M Human genes 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 208000029742 colonic neoplasm Diseases 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 4
- 235000015243 ice cream Nutrition 0.000 description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 239000003381 stabilizer Substances 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- 230000005760 tumorsuppression Effects 0.000 description 4
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 4
- 201000009030 Carcinoma Diseases 0.000 description 3
- PHEDXBVPIONUQT-UHFFFAOYSA-N Cocarcinogen A1 Natural products CCCCCCCCCCCCCC(=O)OC1C(C)C2(O)C3C=C(C)C(=O)C3(O)CC(CO)=CC2C2C1(OC(C)=O)C2(C)C PHEDXBVPIONUQT-UHFFFAOYSA-N 0.000 description 3
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 3
- 102000008070 Interferon-gamma Human genes 0.000 description 3
- 108010074328 Interferon-gamma Proteins 0.000 description 3
- 102000004889 Interleukin-6 Human genes 0.000 description 3
- 108090001005 Interleukin-6 Proteins 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 102100024295 Maltase-glucoamylase Human genes 0.000 description 3
- 241000286209 Phasianidae Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 3
- 239000008186 active pharmaceutical agent Substances 0.000 description 3
- 108010028144 alpha-Glucosidases Proteins 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 3
- 235000013361 beverage Nutrition 0.000 description 3
- 230000004611 cancer cell death Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 230000022131 cell cycle Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 235000015071 dressings Nutrition 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 230000002949 hemolytic effect Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 229960003130 interferon gamma Drugs 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 235000021109 kimchi Nutrition 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 3
- 230000022983 regulation of cell cycle Effects 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 229960004793 sucrose Drugs 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- WQZGKKKJIJFFOK-SVZMEOIVSA-N (+)-Galactose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 description 2
- 206010000050 Abdominal adhesions Diseases 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 241000272517 Anseriformes Species 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 206010003571 Astrocytoma Diseases 0.000 description 2
- 241000186016 Bifidobacterium bifidum Species 0.000 description 2
- 241000186015 Bifidobacterium longum subsp. infantis Species 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 102000001301 EGF receptor Human genes 0.000 description 2
- 108060006698 EGF receptor Proteins 0.000 description 2
- 241000283086 Equidae Species 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 2
- 239000012981 Hank's balanced salt solution Substances 0.000 description 2
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 2
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 2
- 108090001060 Lipase Proteins 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 240000007594 Oryza sativa Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 description 2
- 229920000388 Polyphosphate Polymers 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 2
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 2
- 229940123237 Taxane Drugs 0.000 description 2
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 229940122803 Vinca alkaloid Drugs 0.000 description 2
- 239000005862 Whey Substances 0.000 description 2
- 102000007544 Whey Proteins Human genes 0.000 description 2
- 108010046377 Whey Proteins Proteins 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- PYMYPHUHKUWMLA-LMVFSUKVSA-N aldehydo-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000000340 anti-metabolite Effects 0.000 description 2
- 229940100197 antimetabolite Drugs 0.000 description 2
- 239000002256 antimetabolite Substances 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 102000005936 beta-Galactosidase Human genes 0.000 description 2
- 108010005774 beta-Galactosidase Proteins 0.000 description 2
- 229940002008 bifidobacterium bifidum Drugs 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 235000015155 buttermilk Nutrition 0.000 description 2
- 235000014171 carbonated beverage Nutrition 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 235000013330 chicken meat Nutrition 0.000 description 2
- 229960005091 chloramphenicol Drugs 0.000 description 2
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
- 235000013365 dairy product Nutrition 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 235000021107 fermented food Nutrition 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 229960001031 glucose Drugs 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 229940069445 licorice extract Drugs 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 235000013622 meat product Nutrition 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 210000000581 natural killer T-cell Anatomy 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 229910052697 platinum Inorganic materials 0.000 description 2
- 239000001205 polyphosphate Substances 0.000 description 2
- 235000011176 polyphosphates Nutrition 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 229960003975 potassium Drugs 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 244000144977 poultry Species 0.000 description 2
- 235000013594 poultry meat Nutrition 0.000 description 2
- 235000008476 powdered milk Nutrition 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 229960002920 sorbitol Drugs 0.000 description 2
- 235000013555 soy sauce Nutrition 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 235000013618 yogurt Nutrition 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 description 1
- XUCIJNAGGSZNQT-JHSLDZJXSA-N (R)-amygdalin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O[C@@H](C#N)C=2C=CC=CC=2)O1 XUCIJNAGGSZNQT-JHSLDZJXSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
- GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 description 1
- HVTQDSGGHBWVTR-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-3-phenylmethoxypyrazol-1-yl]-1-morpholin-4-ylethanone Chemical compound C(C1=CC=CC=C1)OC1=NN(C=C1C=1C=NC(=NC=1)NC1CC2=CC=CC=C2C1)CC(=O)N1CCOCC1 HVTQDSGGHBWVTR-UHFFFAOYSA-N 0.000 description 1
- ZRPAUEVGEGEPFQ-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]pyrazol-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C=NN(C=1)CC(=O)N1CC2=C(CC1)NN=N2 ZRPAUEVGEGEPFQ-UHFFFAOYSA-N 0.000 description 1
- VBUYCZFBVCCYFD-JJYYJPOSSA-N 2-dehydro-D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C(=O)C(O)=O VBUYCZFBVCCYFD-JJYYJPOSSA-N 0.000 description 1
- CTRPRMNBTVRDFH-UHFFFAOYSA-N 2-n-methyl-1,3,5-triazine-2,4,6-triamine Chemical compound CNC1=NC(N)=NC(N)=N1 CTRPRMNBTVRDFH-UHFFFAOYSA-N 0.000 description 1
- WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 description 1
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- 108010051457 Acid Phosphatase Proteins 0.000 description 1
- 102000013563 Acid Phosphatase Human genes 0.000 description 1
- PLXMOAALOJOTIY-FPTXNFDTSA-N Aesculin Natural products OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)[C@H]1Oc2cc3C=CC(=O)Oc3cc2O PLXMOAALOJOTIY-FPTXNFDTSA-N 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 206010061424 Anal cancer Diseases 0.000 description 1
- 208000007860 Anus Neoplasms Diseases 0.000 description 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 1
- 235000007319 Avena orientalis Nutrition 0.000 description 1
- 244000075850 Avena orientalis Species 0.000 description 1
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 101710195320 Beta-galactosidase 4 Proteins 0.000 description 1
- 101710099627 Beta-glucosidase 5 Proteins 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 239000005996 Blood meal Substances 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 101000715943 Caenorhabditis elegans Cyclin-dependent kinase 4 homolog Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241001609213 Carassius carassius Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- WNBCMONIPIJTSB-BGNCJLHMSA-N Cichoriin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1)c1c(O)cc2c(OC(=O)C=C2)c1 WNBCMONIPIJTSB-BGNCJLHMSA-N 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 description 1
- 108010025468 Cyclin-Dependent Kinase 6 Proteins 0.000 description 1
- 102100036252 Cyclin-dependent kinase 4 Human genes 0.000 description 1
- 102100026804 Cyclin-dependent kinase 6 Human genes 0.000 description 1
- 241000252233 Cyprinus carpio Species 0.000 description 1
- 108091000069 Cystinyl Aminopeptidase Proteins 0.000 description 1
- 102000030900 Cystinyl aminopeptidase Human genes 0.000 description 1
- HEBKCHPVOIAQTA-NGQZWQHPSA-N D-Arabitol Natural products OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 description 1
- RFSUNEUAIZKAJO-VRPWFDPXSA-N D-Fructose Natural products OC[C@H]1OC(O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-VRPWFDPXSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- HEBKCHPVOIAQTA-QWWZWVQMSA-N D-arabinitol Chemical compound OC[C@@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-QWWZWVQMSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- QWIZNVHXZXRPDR-UHFFFAOYSA-N D-melezitose Natural products O1C(CO)C(O)C(O)C(O)C1OC1C(O)C(CO)OC1(CO)OC1OC(CO)C(O)C(O)C1O QWIZNVHXZXRPDR-UHFFFAOYSA-N 0.000 description 1
- SRBFZHDQGSBBOR-SOOFDHNKSA-N D-ribopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@@H]1O SRBFZHDQGSBBOR-SOOFDHNKSA-N 0.000 description 1
- LKDRXBCSQODPBY-OEXCPVAWSA-N D-tagatose Chemical compound OCC1(O)OC[C@@H](O)[C@H](O)[C@@H]1O LKDRXBCSQODPBY-OEXCPVAWSA-N 0.000 description 1
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- 108010082495 Dietary Plant Proteins Proteins 0.000 description 1
- 208000021994 Diffuse astrocytoma Diseases 0.000 description 1
- 206010061825 Duodenal neoplasm Diseases 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 1
- 208000001976 Endocrine Gland Neoplasms Diseases 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 235000019733 Fish meal Nutrition 0.000 description 1
- 229940123414 Folate antagonist Drugs 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 230000037059 G2/M phase arrest Effects 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 208000021309 Germ cell tumor Diseases 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 102000053187 Glucuronidase Human genes 0.000 description 1
- 108010060309 Glucuronidase Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 244000020551 Helianthus annuus Species 0.000 description 1
- 235000003222 Helianthus annuus Nutrition 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 1
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 1
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 1
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 description 1
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 description 1
- 240000005979 Hordeum vulgare Species 0.000 description 1
- 235000007340 Hordeum vulgare Nutrition 0.000 description 1
- 206010071119 Hormone-dependent prostate cancer Diseases 0.000 description 1
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
- 208000005726 Inflammatory Breast Neoplasms Diseases 0.000 description 1
- 206010021980 Inflammatory carcinoma of the breast Diseases 0.000 description 1
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 description 1
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 description 1
- IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical compound OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 description 1
- 102100022297 Integrin alpha-X Human genes 0.000 description 1
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 1
- 206010073094 Intraductal proliferative breast lesion Diseases 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- LKDRXBCSQODPBY-AMVSKUEXSA-N L-(-)-Sorbose Chemical compound OCC1(O)OC[C@H](O)[C@@H](O)[C@@H]1O LKDRXBCSQODPBY-AMVSKUEXSA-N 0.000 description 1
- SHZGCJCMOBCMKK-PQMKYFCFSA-N L-Fucose Natural products C[C@H]1O[C@H](O)[C@@H](O)[C@@H](O)[C@@H]1O SHZGCJCMOBCMKK-PQMKYFCFSA-N 0.000 description 1
- HEBKCHPVOIAQTA-IMJSIDKUSA-N L-arabinitol Chemical compound OC[C@H](O)C(O)[C@@H](O)CO HEBKCHPVOIAQTA-IMJSIDKUSA-N 0.000 description 1
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- SRBFZHDQGSBBOR-OWMBCFKOSA-N L-ribopyranose Chemical compound O[C@H]1COC(O)[C@@H](O)[C@H]1O SRBFZHDQGSBBOR-OWMBCFKOSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 208000018142 Leiomyosarcoma Diseases 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 208000006552 Lewis Lung Carcinoma Diseases 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000037196 Medullary thyroid carcinoma Diseases 0.000 description 1
- 208000000172 Medulloblastoma Diseases 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 description 1
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 description 1
- DKXNBNKWCZZMJT-UHFFFAOYSA-N O4-alpha-D-Mannopyranosyl-D-mannose Natural products O=CC(O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O DKXNBNKWCZZMJT-UHFFFAOYSA-N 0.000 description 1
- AYRXSINWFIIFAE-UHFFFAOYSA-N O6-alpha-D-Galactopyranosyl-D-galactose Natural products OCC1OC(OCC(O)C(O)C(O)C(O)C=O)C(O)C(O)C1O AYRXSINWFIIFAE-UHFFFAOYSA-N 0.000 description 1
- 101710160107 Outer membrane protein A Proteins 0.000 description 1
- 208000007571 Ovarian Epithelial Carcinoma Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- 208000009565 Pharyngeal Neoplasms Diseases 0.000 description 1
- IMQLKJBTEOYOSI-UHFFFAOYSA-N Phytic acid Natural products OP(O)(=O)OC1C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C1OP(O)(O)=O IMQLKJBTEOYOSI-UHFFFAOYSA-N 0.000 description 1
- 208000007913 Pituitary Neoplasms Diseases 0.000 description 1
- 201000005746 Pituitary adenoma Diseases 0.000 description 1
- 206010061538 Pituitary tumour benign Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- HLCFGWHYROZGBI-JJKGCWMISA-M Potassium gluconate Chemical compound [K+].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O HLCFGWHYROZGBI-JJKGCWMISA-M 0.000 description 1
- 229940079156 Proteasome inhibitor Drugs 0.000 description 1
- 229940123924 Protein kinase C inhibitor Drugs 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 102000015690 Proto-Oncogene Proteins c-bcr Human genes 0.000 description 1
- 108010024221 Proto-Oncogene Proteins c-bcr Proteins 0.000 description 1
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 description 1
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 description 1
- 239000012979 RPMI medium Substances 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 244000178231 Rosmarinus officinalis Species 0.000 description 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 1
- NGFMICBWJRZIBI-JZRPKSSGSA-N Salicin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O1)c1c(CO)cccc1 NGFMICBWJRZIBI-JZRPKSSGSA-N 0.000 description 1
- 241000277331 Salmonidae Species 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- 206010054184 Small intestine carcinoma Diseases 0.000 description 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 description 1
- 240000003768 Solanum lycopersicum Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 229940100514 Syk tyrosine kinase inhibitor Drugs 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 101710165436 Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 description 1
- 239000004182 Tylosin Substances 0.000 description 1
- 229930194936 Tylosin Natural products 0.000 description 1
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 108010059993 Vancomycin Proteins 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 201000008395 adenosquamous carcinoma Diseases 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- PNNNRSAQSRJVSB-DPYQTVNSSA-N aldehydo-D-fucose Chemical compound C[C@@H](O)[C@H](O)[C@H](O)[C@@H](O)C=O PNNNRSAQSRJVSB-DPYQTVNSSA-N 0.000 description 1
- PNNNRSAQSRJVSB-BXKVDMCESA-N aldehydo-L-rhamnose Chemical compound C[C@H](O)[C@H](O)[C@@H](O)[C@@H](O)C=O PNNNRSAQSRJVSB-BXKVDMCESA-N 0.000 description 1
- PYMYPHUHKUWMLA-WISUUJSJSA-N aldehydo-L-xylose Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WISUUJSJSA-N 0.000 description 1
- 229930195726 aldehydo-L-xylose Natural products 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000008052 alkyl sulfonates Chemical class 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 230000002152 alkylating effect Effects 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- SRBFZHDQGSBBOR-STGXQOJASA-N alpha-D-lyxopyranose Chemical compound O[C@@H]1CO[C@H](O)[C@@H](O)[C@H]1O SRBFZHDQGSBBOR-STGXQOJASA-N 0.000 description 1
- 102000005840 alpha-Galactosidase Human genes 0.000 description 1
- 108010030291 alpha-Galactosidase Proteins 0.000 description 1
- 102000012086 alpha-L-Fucosidase Human genes 0.000 description 1
- 108010061314 alpha-L-Fucosidase Proteins 0.000 description 1
- 102000019199 alpha-Mannosidase Human genes 0.000 description 1
- 108010012864 alpha-Mannosidase Proteins 0.000 description 1
- 108010027597 alpha-chymotrypsin Proteins 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- NGFMICBWJRZIBI-UHFFFAOYSA-N alpha-salicin Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=CC=C1CO NGFMICBWJRZIBI-UHFFFAOYSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 229940089837 amygdalin Drugs 0.000 description 1
- YZLOSXFCSIDECK-UHFFFAOYSA-N amygdalin Natural products OCC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC(C#N)c3ccccc3 YZLOSXFCSIDECK-UHFFFAOYSA-N 0.000 description 1
- 239000006053 animal diet Substances 0.000 description 1
- 235000021120 animal protein Nutrition 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000001772 anti-angiogenic effect Effects 0.000 description 1
- 229940124650 anti-cancer therapies Drugs 0.000 description 1
- 239000002543 antimycotic Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 201000011165 anus cancer Diseases 0.000 description 1
- 229960000271 arbutin Drugs 0.000 description 1
- 229960005370 atorvastatin Drugs 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- 235000015241 bacon Nutrition 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 229940004120 bifidobacterium infantis Drugs 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 229940093761 bile salts Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 239000006161 blood agar Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229940036811 bone meal Drugs 0.000 description 1
- 239000002374 bone meal Substances 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- KQNZDYYTLMIZCT-KQPMLPITSA-N brefeldin A Chemical compound O[C@@H]1\C=C\C(=O)O[C@@H](C)CCC\C=C\[C@@H]2C[C@H](O)C[C@H]21 KQNZDYYTLMIZCT-KQPMLPITSA-N 0.000 description 1
- JUMGSHROWPPKFX-UHFFFAOYSA-N brefeldin-A Natural products CC1CCCC=CC2(C)CC(O)CC2(C)C(O)C=CC(=O)O1 JUMGSHROWPPKFX-UHFFFAOYSA-N 0.000 description 1
- BMQGVNUXMIRLCK-OAGWZNDDSA-N cabazitaxel Chemical compound O([C@H]1[C@@H]2[C@]3(OC(C)=O)CO[C@@H]3C[C@@H]([C@]2(C(=O)[C@H](OC)C2=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=3C=CC=CC=3)C[C@]1(O)C2(C)C)C)OC)C(=O)C1=CC=CC=C1 BMQGVNUXMIRLCK-OAGWZNDDSA-N 0.000 description 1
- 229960001573 cabazitaxel Drugs 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 230000005880 cancer cell killing Effects 0.000 description 1
- 229940022399 cancer vaccine Drugs 0.000 description 1
- 238000009566 cancer vaccine Methods 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 208000025188 carcinoma of pharynx Diseases 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 210000005056 cell body Anatomy 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000002771 cell marker Substances 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 229960005110 cerivastatin Drugs 0.000 description 1
- SEERZIQQUAZTOL-ANMDKAQQSA-N cerivastatin Chemical compound COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 SEERZIQQUAZTOL-ANMDKAQQSA-N 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 229940045110 chitosan Drugs 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 208000006990 cholangiocarcinoma Diseases 0.000 description 1
- 230000035603 choleresis Effects 0.000 description 1
- 229950001002 cianidanol Drugs 0.000 description 1
- 230000001886 ciliary effect Effects 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 229960002227 clindamycin Drugs 0.000 description 1
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 235000015140 cultured milk Nutrition 0.000 description 1
- 235000021438 curry Nutrition 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 229960000640 dactinomycin Drugs 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 201000000312 duodenum cancer Diseases 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 229960001484 edetic acid Drugs 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 201000011523 endocrine gland cancer Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- 229960001904 epirubicin Drugs 0.000 description 1
- 208000037828 epithelial carcinoma Diseases 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 229940093496 esculin Drugs 0.000 description 1
- XHCADAYNFIFUHF-TVKJYDDYSA-N esculin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C(=C1)O)=CC2=C1OC(=O)C=C2 XHCADAYNFIFUHF-TVKJYDDYSA-N 0.000 description 1
- AWRMZKLXZLNBBK-UHFFFAOYSA-N esculin Natural products OC1OC(COc2cc3C=CC(=O)Oc3cc2O)C(O)C(O)C1O AWRMZKLXZLNBBK-UHFFFAOYSA-N 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- YGHHWSRCTPQFFC-UHFFFAOYSA-N eucalyptosin A Natural products OC1C(O)C(O)C(CO)OC1OC1C(OC(C#N)C=2C=CC=CC=2)OC(CO)C(O)C1O YGHHWSRCTPQFFC-UHFFFAOYSA-N 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 208000020603 familial colorectal cancer Diseases 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 201000001169 fibrillary astrocytoma Diseases 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 235000013332 fish product Nutrition 0.000 description 1
- 239000004467 fishmeal Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000012757 fluorescence staining Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 229960003765 fluvastatin Drugs 0.000 description 1
- 239000004052 folic acid antagonist Substances 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 235000010610 frozen noodles Nutrition 0.000 description 1
- 235000021456 frozen pasta Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- FBPFZTCFMRRESA-GUCUJZIJSA-N galactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-GUCUJZIJSA-N 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 238000012812 general test Methods 0.000 description 1
- 238000012252 genetic analysis Methods 0.000 description 1
- DLRVVLDZNNYCBX-CQUJWQHSSA-N gentiobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-CQUJWQHSSA-N 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 235000020251 goat milk Nutrition 0.000 description 1
- 235000020688 green tea extract Nutrition 0.000 description 1
- 229940094952 green tea extract Drugs 0.000 description 1
- 239000007952 growth promoter Substances 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 235000015220 hamburgers Nutrition 0.000 description 1
- 230000008821 health effect Effects 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 1
- SUSRLLXAXAIZPH-OBPIAQAESA-N hydroquinone beta-D-glucopyranoside Natural products OC[C@H]1O[C@@H](Cc2ccc(O)cc2)[C@H](O)[C@@H](O)[C@@H]1O SUSRLLXAXAIZPH-OBPIAQAESA-N 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 229960000908 idarubicin Drugs 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 230000003832 immune regulation Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 201000004653 inflammatory breast carcinoma Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 206010073095 invasive ductal breast carcinoma Diseases 0.000 description 1
- 201000010985 invasive ductal carcinoma Diseases 0.000 description 1
- PGHMRUGBZOYCAA-UHFFFAOYSA-N ionomycin Natural products O1C(CC(O)C(C)C(O)C(C)C=CCC(C)CC(C)C(O)=CC(=O)C(C)CC(C)CC(CCC(O)=O)C)CCC1(C)C1OC(C)(C(C)O)CC1 PGHMRUGBZOYCAA-UHFFFAOYSA-N 0.000 description 1
- PGHMRUGBZOYCAA-ADZNBVRBSA-N ionomycin Chemical compound O1[C@H](C[C@H](O)[C@H](C)[C@H](O)[C@H](C)/C=C/C[C@@H](C)C[C@@H](C)C(/O)=C/C(=O)[C@@H](C)C[C@@H](C)C[C@@H](CCC(O)=O)C)CC[C@@]1(C)[C@@H]1O[C@](C)([C@@H](C)O)CC1 PGHMRUGBZOYCAA-ADZNBVRBSA-N 0.000 description 1
- 229960004768 irinotecan Drugs 0.000 description 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 235000008960 ketchup Nutrition 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 210000000244 kidney pelvis Anatomy 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 229950005692 larotaxel Drugs 0.000 description 1
- SEFGUGYLLVNFIJ-QDRLFVHASA-N larotaxel dihydrate Chemical compound O.O.O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@@]23[C@H]1[C@@]1(CO[C@@H]1C[C@@H]2C3)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 SEFGUGYLLVNFIJ-QDRLFVHASA-N 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 229960004844 lovastatin Drugs 0.000 description 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
- 235000020121 low-fat milk Nutrition 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 208000006178 malignant mesothelioma Diseases 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 229960002160 maltose Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 229960004961 mechlorethamine Drugs 0.000 description 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical class ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
- 208000023356 medullary thyroid gland carcinoma Diseases 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- QWIZNVHXZXRPDR-WSCXOGSTSA-N melezitose Chemical compound O([C@@]1(O[C@@H]([C@H]([C@@H]1O[C@@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O)CO)CO)[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O QWIZNVHXZXRPDR-WSCXOGSTSA-N 0.000 description 1
- DLRVVLDZNNYCBX-ABXHMFFYSA-N melibiose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-ABXHMFFYSA-N 0.000 description 1
- HOVAGTYPODGVJG-ZFYZTMLRSA-N methyl alpha-D-glucopyranoside Chemical compound CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HOVAGTYPODGVJG-ZFYZTMLRSA-N 0.000 description 1
- HOVAGTYPODGVJG-VEIUFWFVSA-N methyl alpha-D-mannoside Chemical compound CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]1O HOVAGTYPODGVJG-VEIUFWFVSA-N 0.000 description 1
- ZBDGHWFPLXXWRD-JGWLITMVSA-N methyl beta-D-xylopyranoside Chemical compound CO[C@@H]1OC[C@@H](O)[C@H](O)[C@H]1O ZBDGHWFPLXXWRD-JGWLITMVSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 229960001156 mitoxantrone Drugs 0.000 description 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- HDZGCSFEDULWCS-UHFFFAOYSA-N monomethylhydrazine Chemical class CNN HDZGCSFEDULWCS-UHFFFAOYSA-N 0.000 description 1
- 235000013923 monosodium glutamate Nutrition 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 201000010879 mucinous adenocarcinoma Diseases 0.000 description 1
- 210000000066 myeloid cell Anatomy 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 235000019462 natural additive Nutrition 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 125000000018 nitroso group Chemical group N(=O)* 0.000 description 1
- OSTGTTZJOCZWJG-UHFFFAOYSA-N nitrosourea Chemical compound NC(=O)N=NO OSTGTTZJOCZWJG-UHFFFAOYSA-N 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 244000309459 oncolytic virus Species 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 208000021284 ovarian germ cell tumor Diseases 0.000 description 1
- 229960001756 oxaliplatin Drugs 0.000 description 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
- -1 pH adjusters Substances 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 229940124641 pain reliever Drugs 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 230000009996 pancreatic endocrine effect Effects 0.000 description 1
- 208000004019 papillary adenocarcinoma Diseases 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000000467 phytic acid Substances 0.000 description 1
- 235000002949 phytic acid Nutrition 0.000 description 1
- 229940068041 phytic acid Drugs 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 201000007315 pineal gland astrocytoma Diseases 0.000 description 1
- 229960002797 pitavastatin Drugs 0.000 description 1
- VGYFMXBACGZSIL-MCBHFWOFSA-N pitavastatin Chemical compound OC(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 VGYFMXBACGZSIL-MCBHFWOFSA-N 0.000 description 1
- 208000021310 pituitary gland adenoma Diseases 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 208000015768 polyposis Diseases 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- 239000004224 potassium gluconate Substances 0.000 description 1
- 229960003189 potassium gluconate Drugs 0.000 description 1
- 235000013926 potassium gluconate Nutrition 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 235000014059 processed cheese Nutrition 0.000 description 1
- 235000020991 processed meat Nutrition 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 239000003207 proteasome inhibitor Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000003528 protein farnesyltransferase inhibitor Substances 0.000 description 1
- 239000003881 protein kinase C inhibitor Substances 0.000 description 1
- 239000000649 purine antagonist Substances 0.000 description 1
- 239000003790 pyrimidine antagonist Substances 0.000 description 1
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 1
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- HEBKCHPVOIAQTA-ZXFHETKHSA-N ribitol Chemical compound OC[C@H](O)[C@H](O)[C@H](O)CO HEBKCHPVOIAQTA-ZXFHETKHSA-N 0.000 description 1
- NGFMICBWJRZIBI-UJPOAAIJSA-N salicin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=CC=C1CO NGFMICBWJRZIBI-UJPOAAIJSA-N 0.000 description 1
- 229940120668 salicin Drugs 0.000 description 1
- 235000015067 sauces Nutrition 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 229960002855 simvastatin Drugs 0.000 description 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 201000002314 small intestine cancer Diseases 0.000 description 1
- 229940073490 sodium glutamate Drugs 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 230000037351 starvation Effects 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 description 1
- 229940033123 tannic acid Drugs 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 208000013818 thyroid gland medullary carcinoma Diseases 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 229960000303 topotecan Drugs 0.000 description 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- BSUNTQCMCCQSQH-UHFFFAOYSA-N triazine Chemical compound C1=CN=NN=C1.C1=CN=NN=C1 BSUNTQCMCCQSQH-UHFFFAOYSA-N 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 230000002100 tumorsuppressive effect Effects 0.000 description 1
- RULSWEULPANCDV-PIXUTMIVSA-N turanose Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](C(=O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O RULSWEULPANCDV-PIXUTMIVSA-N 0.000 description 1
- WBPYTXDJUQJLPQ-VMXQISHHSA-N tylosin Chemical compound O([C@@H]1[C@@H](C)O[C@H]([C@@H]([C@H]1N(C)C)O)O[C@@H]1[C@@H](C)[C@H](O)CC(=O)O[C@@H]([C@H](/C=C(\C)/C=C/C(=O)[C@H](C)C[C@@H]1CC=O)CO[C@H]1[C@@H]([C@H](OC)[C@H](O)[C@@H](C)O1)OC)CC)[C@H]1C[C@@](C)(O)[C@@H](O)[C@H](C)O1 WBPYTXDJUQJLPQ-VMXQISHHSA-N 0.000 description 1
- 229960004059 tylosin Drugs 0.000 description 1
- 235000019375 tylosin Nutrition 0.000 description 1
- 210000000626 ureter Anatomy 0.000 description 1
- 201000007433 ureter carcinoma Diseases 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 208000037965 uterine sarcoma Diseases 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 229960003165 vancomycin Drugs 0.000 description 1
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 1
- MYPYJXKWCTUITO-LYRMYLQWSA-O vancomycin(1+) Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C([O-])=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)[NH2+]C)[C@H]1C[C@](C)([NH3+])[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-O 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 1
- 229960002066 vinorelbine Drugs 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
- A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
- A23K10/18—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions of live microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/308—Foods, ingredients or supplements having a functional effect on health having an effect on cancer prevention
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Definitions
- the present application relates to a novel Leuconostoc mesenteroides strain, a composition for preventing, improving or treating cancer or inflammation comprising a culture thereof or a component derived therefrom, a composition for enhancing immunity including the same, and using the same It relates to a method for preventing or treating cancer or inflammation.
- Cancer is an abnormal cell growth caused by various changes in gene expression, infiltrating and destroying adjacent tissues, metastasizing to distant locations, and eventually leading to death.
- Cancer has a high mortality rate worldwide and is the second most common cause of death in Western societies after cardiovascular disease.
- dietary habits have become westernized, high-fat diet intake has become common, and colorectal cancer, lung cancer, breast cancer, and the like are continuously increasing due to a rapid increase in environmental pollutants and an increase in alcohol consumption.
- lactic acid bacteria are closely related to the health of humans and animals while widely distributed in the mouth, intestines, vagina, feces of humans and animals, and fermented foods such as yogurt, cheonggukjang, and kimchi. Lactic acid bacteria have been reported to exhibit various health-promoting effects such as intestinal regulation, suppression of harmful bacteria, immune regulation, blood cholesterol lowering, and anticancer (WO2022-103138 A1).
- the present application relates to a novel Leuconostoc mesenteroides strain, a composition for preventing, improving or treating cancer or inflammation comprising a culture thereof or a component derived therefrom, a composition for enhancing immunity including the same, and using the same
- a method for preventing or treating cancer or inflammation is provided.
- One object of the present application is to provide a pharmaceutical composition for the prevention or treatment of lung cancer or breast cancer, comprising a Leuconostoc mesenteroides strain, a culture thereof, or a component derived therefrom as an active ingredient. .
- Leukonostok Mecenteroides Leukonostok mecenteroides
- CJRS-10671 Accession No. KCCM13059P
- Leukonostok Mecenteroides CJRS-10672 Accession No. KCCM13060P
- Another object of the present application is to provide a method for preventing or treating cancer, comprising administering the pharmaceutical composition of the present application to a subject.
- Another object of the present application is Leuconostoc mesenteroides CJRS-10671 (Accession No. KCCM13059P) or Leuconostoc Mesenteroides CJRS-10672 (Accession No. KCCM13060P); its culture; Or to provide a pharmaceutical composition for preventing or treating colorectal cancer, comprising a component derived therefrom as an active ingredient, and administered in combination with an anticancer agent.
- Another object of the present application is to provide a method for preventing or treating lung cancer, breast cancer or colon cancer comprising administering the pharmaceutical composition of the present application to a subject.
- Another object of the present application is to provide a food composition for preventing or improving lung cancer, breast cancer or colorectal cancer, comprising a strain of Leuconostoc mecenteroides, a culture thereof, or a component derived therefrom as an active ingredient.
- Another object of the present application is to provide a health functional food for preventing or improving lung cancer, breast cancer or colorectal cancer, including a Leuconostoc mecenteroides strain, its culture, or a component derived therefrom as an active ingredient. .
- Another object of the present application is to provide a feed composition for preventing or improving lung cancer, breast cancer or colorectal cancer, including a Leuconostoc mecenteroides strain, a culture thereof, or a component derived therefrom as an active ingredient.
- Another object of the present application is Leuconostoc mesenteroides CJRS-10671 (Accession No. KCCM13059P) or Leuconostoc Mesenteroides CJRS-10672 (Accession No. KCCM13060P); its culture; Or to provide a food composition for preventing or improving cancer or inflammation, comprising a component derived therefrom as an active ingredient.
- Another object of the present application is Leuconostoc mesenteroides CJRS-10671 (Accession No. KCCM13059P) or Leuconostoc Mesenteroides CJRS-10672 (Accession No. KCCM13060P); its culture; Or to provide a health functional food for preventing or improving cancer or inflammation, containing a component derived therefrom as an active ingredient.
- Another object of the present application is Leuconostoc mesenteroides CJRS-10671 (Accession No. KCCM13059P) or Leuconostoc Mesenteroides CJRS-10672 (Accession No. KCCM13060P); its culture; Or to provide a feed composition for preventing or improving cancer or inflammation, comprising a component derived therefrom as an active ingredient.
- Another object of the present application is Leuconostoc mesenteroides CJRS-10671 (Accession No. KCCM13059P) or Leuconostoc Mesenteroides CJRS-10672 (Accession No. KCCM13060P); its culture; Or to provide a pharmaceutical composition for enhancing immunity, comprising a component derived therefrom as an active ingredient.
- Another object of the present application is Leuconostoc mesenteroides CJRS-10671 (Accession No. KCCM13059P) or Leuconostoc Mesenteroides CJRS-10672 (Accession No. KCCM13060P); its culture; Or to provide a food composition for enhancing immunity, comprising a component derived therefrom as an active ingredient.
- Another object of the present application is Leuconostoc mesenteroides CJRS-10671 (Accession No. KCCM13059P) or Leuconostoc Mesenteroides CJRS-10672 (Accession No. KCCM13060P); its culture; Or to provide a health functional food for enhancing immunity, containing a component derived therefrom as an active ingredient.
- Another object of the present application is Leuconostoc mesenteroides CJRS-10671 (Accession No. KCCM13059P) or Leuconostoc Mesenteroides CJRS-10672 (Accession No. KCCM13060P); its culture; Or to provide a feed composition for enhancing immunity, comprising a component derived therefrom as an active ingredient.
- the novel Leuconostoc mesenteroides strain exhibits anticancer and anti-inflammatory effects, and enhances CD8 T cell function to secrete immune-enhancing cytokines IL-6, IL-12p70 and IFN ⁇ It can be applied for prevention or treatment of cancer or inflammation, or for immunity enhancement purposes.
- 1 is a view confirming the enzyme activity of Leuconostoc mesenteroides CJRS-10671 and CJRS-10672 strains.
- Figure 2 is a diagram confirming the hemolytic properties of CJRS-10671 and CJRS-10672 strains.
- 3 is a diagram confirming the intestinal attachment ability of CJRS-10671 and CJRS-10672 strains.
- Figure 4 is a diagram confirming IL (interleukin) -6 secretion due to CJRS-10671 and CJRS-10672 strains in macrophage cell lines.
- FIG. 5 is a diagram confirming IL-12p70 secretion by CJRS-10671 and CJRS-10672 strains in human PBMC (peripheral blood mononuclear cells).
- FIG. 6 is a diagram confirming the IFN ⁇ (Interferon-gamma) secretion ability of CD8 T cells caused by CJRS-10671 and CJRS-10672 strains in mouse splenocytes and human PBMC.
- IFN ⁇ Interferon-gamma
- FIG. 7 is a diagram confirming the cell cycle arrest effect of cancer cells caused by CJRS-10671 and CJRS-10672 strains.
- cyclin B1 cyclin B1
- CDK1 cyclin dependent kinase 1
- FIG. 9 is a diagram confirming cancer cell death caused by CJRS-10671 and CJRS-10672 strains.
- FIG. 10 is a diagram confirming the tumor suppression effect by administration of CJRS-10671 and CJRS-10672 in a mouse lung cancer model (LLC1).
- FIG. 11 is a diagram confirming the IFN ⁇ secretion ability of CD8 T cells by CJRS-10671 administration in a mouse lung cancer model (LLC1).
- FIG. 12 is a diagram confirming the IFN ⁇ secretion ability of CD8 T cells by CJRS-10672 administration in a mouse lung cancer model (LLC1).
- FIG. 13 is a diagram confirming the IFN ⁇ secretion ability of CD8 T cells in tumor tissue by administration of CJRS-10671 and CJRS-10672 in a mouse lung cancer model (LLC1).
- FIG. 14 is a diagram confirming changes in myeloid-derived suppressor cells (MDSC), which are immunosuppressive cells, by administration of CJRS-10671 and CJRS-10672 in a mouse lung cancer model (LLC1).
- MDSC myeloid-derived suppressor cells
- LLC 15 is a diagram confirming immune cell profiling by CJRS-10671 administration in a mouse lung cancer model (LLC1).
- 16 is a diagram confirming immune cell profiling by CJRS-10672 administration in a mouse lung cancer model (LLC1).
- 17 is a diagram confirming the tumor suppression effect by CJRS-10672 administration in a mouse breast cancer model (4T1).
- One aspect of the present application provides a pharmaceutical composition for preventing or treating lung cancer or breast cancer, comprising a Leuconostoc mesenteroides strain, a culture thereof, or a component derived therefrom as an active ingredient. .
- Leuconostoc mesenteroides refers to lactic acid bacteria having a round, spherical shape, and is known as lactic acid bacteria fermenting foods such as probiotics or kimchi.
- the Leuconostoc mesenteroides strain of the present application may be any one or more selected from CJRS-10671 deposited under accession number KCCM13059P or CJRS-10672 deposited under accession number KCCM13060P.
- CJRS-10671 strain of the present application may have high enzymatic activities of ⁇ -galactosidase, ⁇ -glucosidase and ⁇ -glucosidase
- the CJRS-10672 strain of the application may have high enzymatic activity of ⁇ -glucosidase.
- strain of the present application may have a suitability effect and an immune enhancing effect.
- the strain of the present application included in the composition according to the present application may exist as live cells or dead cells, and may also exist in a dried or lyophilized form.
- the culture of the present application includes a live cell culture (ie, a result of culturing live cells in a medium), a culture obtained by killing live cells in the live cell culture, or a culture filtrate (ie, dead cells or live cells removed from the culture). results) may be included.
- the component derived from the strain of the present application may include, for example, a cytoplasmic fraction obtained by disrupting the cell body containing EV (Extracellular Vesicle) and the like.
- the type of lactic acid bacteria suitable for inclusion in a pharmaceutical composition, a formulation method, and a method for separating components derived from strains are well known to those skilled in the art.
- the strain of the present application may be a strain cultured at 25 to 40 ° C. for 4 to 72 hours by inoculating 0.1 to 10% in MRS liquid medium.
- composition of the present application may be administered in combination with an anticancer agent.
- Leuconostoc Mesenteroides CJRS-10671 (Accession No. KCCM13059P) or Leuconostoc Mesenteroides CJRS-10672 (Accession No. KCCM13060P); its culture; Or it provides a pharmaceutical composition for preventing or treating colorectal cancer, comprising a component derived therefrom as an active ingredient, and administered in combination with an anticancer agent.
- strain, culture, and derived components are as described above.
- the strain of the present application may exhibit anticancer, anti-inflammatory and immune enhancing effects.
- prevention refers to any activity that inhibits or delays the onset of cancer by administering the composition of the present application
- treatment means that the symptoms of cancer are improved or beneficial by administration of the composition of the present application. It means any action that changes.
- cancer may include any cancer known in the art without limitation, and for example, lung cancer (eg, non-small cell lung cancer, small cell lung cancer, malignant mesothelioma), mesothelioma, pancreatic cancer (eg, pancreatic ductal cancer, pancreatic endocrine tumor) ), cancer of the pharynx, larynx, esophagus, stomach (e.g. papillary adenocarcinoma, mucinous adenocarcinoma, adenosquamous carcinoma), duodenal cancer, small intestine cancer, colon cancer (e.g.
- colon cancer rectal cancer, anal cancer, familial colorectal cancer, hereditary Nasal polyposis colorectal cancer, digestive stromal tumors), breast cancer (eg, invasive ductal carcinoma, noninvasive ductal carcinoma, inflammatory breast cancer), ovarian cancer (eg, epithelial ovarian carcinoma, extratesticular germ cell tumor, ovarian germ cell tumor, ovarian low-grade tumors), testicular tumors, prostate cancer (eg, hormone-dependent prostate cancer, hormone-independent prostate cancer), liver cancer (eg, hepatocellular carcinoma, primary liver cancer, extrahepatic cholangiocarcinoma), thyroid cancer (eg, medullary thyroid carcinoma) , renal cancer (e.g.
- renal cell carcinoma transitional epithelial carcinoma of the renal pelvis and ureter
- uterine cancer e.g. cervical cancer, endometrial cancer, uterine sarcoma
- brain tumor e.g. medulloblastoma, glioma, pineal astrocytoma, ciliary cell tumor
- astrocytoma diffuse astrocytoma, degenerative astrocytoma, pituitary adenoma
- retinoblastoma skin cancer (e.g., basal cell carcinoma, malignant melanoma), sarcoma (e.g., rhabdomyosarcoma, leiomyosarcoma, soft tissue sarcoma), malignant bone tumor
- It may be bladder cancer, hematological cancer (eg, multiple myeloma, leukemia, malignant lymphoma, Hodgkin's disease, chronic myeloproliferative disease), primary cancer of unknown origin, and
- the pharmaceutical composition of the present application may be administered through any general route as long as the composition of the present application can reach the target tissue.
- various forms of administration may be considered, including intraperitoneal administration, intravenous administration, intramuscular administration, subcutaneous administration, intradermal administration, oral administration, topical administration, intranasal administration, intrapulmonary administration, intrarectal administration, but the present application is not limited to these exemplary forms of administration.
- the composition may be administered in the form of an injection.
- the pharmaceutical composition may be administered by a specific device capable of transporting active ingredients to target cells.
- the pharmaceutical composition of the present application may further include a pharmaceutically acceptable carrier.
- the pharmaceutically acceptable carrier may include a binder, a lubricant, a disintegrant, an excipient, a solubilizer, a dispersing agent, a stabilizer, a suspending agent, a colorant, and a flavoring agent.
- the pharmaceutically acceptable carrier may include a buffer, a preservative, a pain reliever, a solubilizer, an isotonic agent, and a stabilizer.
- pharmaceutically acceptable carriers may include bases, excipients, lubricants and preservatives.
- the dosage form of the pharmaceutical composition of the present application may be prepared in various dosage forms by combining the pharmaceutically acceptable carrier as described above.
- the pharmaceutically acceptable carrier for oral administration, it may be formulated as a tablet, troche, capsule, elixir, suspension, syrup or wafer.
- it may be formulated as a multi-dose formulation such as an ampoule of unit dosage form or a multi-dose container.
- the composition may also be formulated as solutions, suspensions, tablets, pills, capsules, and sustained-release preparations.
- examples of carriers, excipients and diluents suitable for formulation include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia gum, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil.
- fillers, anti-agglomerating agents, lubricants, wetting agents, flavoring agents and preservatives may be further included.
- the pharmaceutical composition of the present application can be administered in a pharmaceutically effective amount.
- the term "pharmaceutically effective amount” means an amount sufficient to treat a disease with a reasonable benefit/risk ratio applicable to medical treatment, and the effective dose level is dependent on the type and severity of the subject, age, sex, and disease. It may be determined according to factors including type, activity of drug, sensitivity to drug, administration time, route of administration and excretion rate, duration of treatment, drugs used concurrently, and other factors well known in the medical field.
- the pharmaceutical composition of the present application may be administered as an individual therapeutic agent or in combination with other therapeutic agents, and may be administered sequentially or simultaneously with conventional therapeutic agents. And it can be single or multiple administrations.
- a preferred dosage of the pharmaceutical composition of the present application may be determined by various factors including the type of anticancer agent as well as the type of carcinoma to be treated, the route of administration, the patient's age, sex, weight, and severity of the disease.
- the pharmaceutical composition of the present application is administered in combination with an anticancer agent, the dose of the anticancer agent administered in combination can be reduced, thereby reducing the side effects of the anticancer agent and increasing patient compliance.
- Administration may be administered once a day, or may be administered in several divided doses.
- the pharmaceutical composition of the present application may be used in the form of animal medicines as well as medicines applied to humans.
- the animal is a concept including livestock and companion animals.
- the pharmaceutical composition of the present application may be administered in combination with an anticancer agent.
- the anti-cancer agents for example, taxane-based anti-cancer agents, statins, alkylating agents, platinum-based drugs, antimetabolites, antibiotics, vinca alkaloids anti-cancer agents, It may be a targeted therapy, an immune anti-cancer agent, a cancer vaccine, a cell therapy, an oncolytic virus, and a combination thereof, but is not limited thereto, and may specifically be an immune anti-cancer agent.
- taxane-based anticancer agent examples include, but are not limited to, paclitaxel, docetaxel, larotaxel, and cabazitaxel.
- the statin may be, for example, simvastatin, atorvastatin, lovastatin, fluvastatin, cerivastatin, and pitavastatin, but is not limited thereto.
- alkylating drug examples include nitrogen mustard-based drugs, ethylenimine and methylmelamine-based drugs, methylhydrazine derivatives, alkyl sulfonate-based drugs, nitroso It may be a urea (Nitrosourea) drug and a triazine (Triazine) based drug, etc., but is not limited thereto.
- the platinum agent may be, for example, Cisplatin, Carboplatin, and Oxaliplatin, but is not limited thereto.
- the antimetabolite may be, for example, a folate antagonist drug, a purine antagonist drug, and a pyrimidine antagonist drug, but is not limited thereto.
- the antibiotic is, for example, Etoposide, Topotecan, Irinotecan, Idarubicin, Epirubicin, Dactinomycin, Doxorubicin, Adriamycin ), daunorubicin, bleomycin, mitomycin-C, and mitoxantrone, but not limited thereto.
- the vinca alkaloid-based anticancer agent may be, for example, vincristine, vinblastine, and vinorelbine, but is not limited thereto.
- the targeted therapy is, for example, EGFR (Epidermal growth factor receptor) targeted therapy, HER2 (Human Epidermal growth factor Receptor 2) targeted therapy, CD20 (B cell marker) targeted therapy, CD33 (Myeloid Cell Surface Antigen) targeted therapy, CD52 ( cluster of differentiation 52) targeted therapy, CD30 (Tumor Necrosis Factor Receptor Superfamily Member 8) targeted therapy, bcr-abl (breakpoint cluster region protein-tyrosine-protein kinase)/c-Kit (tyrosine kinase receptor) targeted therapy, ALK (anaplastic) lymphoma receptor tyrosine kinase) targeted therapy, antiangiogenics targeted therapy, mTOR (Mammalian target of rapamycin) targeted therapy, CDK4/6 (Cyclin-dependent kinase 4/6) targeted therapy, PARP (Poly (ADP-ribose) ) polymerase) targeted therapeutic agents, proteasome inhibitors, tyrosine
- the immune anticancer agent is, for example, anti-PD-1 (programmed cell death protein 1,), anti-PD-L1 (programmed cell death-ligand 1), CTLA4 (Cytotoxic T Lymphocyte associated Antigen 4), CTLA4/B7-1 /B7-2 interaction inhibitor and CD47/SIRP (Cluster of Differentiation 47/Signal-regulatory protein) interaction inhibitor, anti-Tim3 (T-cell immunoglobulin and mucin domain 3) and anti-LAG3 (Lymphocyte Activating 3), etc.
- anti-PD-1 programmeed cell death protein 1
- anti-PD-L1 programmeed cell death-ligand 1
- CTLA4 Cytotoxic T Lymphocyte associated Antigen 4
- CTLA4/B7-1 /B7-2 interaction inhibitor and CD47/SIRP (Cluster of Differentiation 47/Signal-regulatory protein) interaction inhibitor
- anti-Tim3 T-cell immunoglobulin and mucin domain 3
- anti-LAG3
- the anti-cancer agent of the present application may be, but is not limited to, an anti-PD-1 immune anti-cancer agent.
- the combined administration may be the simultaneous, sequential or reverse administration of the pharmaceutical composition and the anticancer agent, but the order of administration is not limited and as long as it is administered at an administration interval that can exert both pharmacological effects, belong to the category
- the pharmaceutical composition and the anticancer agent may be individually formulated, or may be formulated as one formulation, but is not limited thereto.
- administration of the pharmaceutical composition of the present application may be combined with anti-cancer therapy.
- the anticancer therapy may be radiotherapy, neoadjuvant therapy, chemotherapy, targeted therapy, photodynamic therapy, and the like, but is not limited thereto and is known in the art. All known anti-cancer therapies may be included.
- the pharmaceutical composition of the present application may exhibit an anticancer effect.
- the anticancer effect may include cancer cell killing or tumor growth inhibitory effects (Examples 9 and 10-1).
- the pharmaceutical composition of the present application may exhibit an anti-cancer effect by inhibiting the cell cycle of cancer cells, thereby suppressing cancer cell death or tumor growth (Example 8).
- the pharmaceutical composition of the present application may exhibit an anti-inflammatory or immune enhancing effect by increasing the secretion of immune enhancing cytokines IL (interlukine) -6, IL-12p70 and IFN ⁇ (Interferon-gamma) ( Example 7).
- Another aspect of the present application provides a method for preventing or treating lung cancer, breast cancer or colon cancer comprising administering the pharmaceutical composition of the present application to a subject.
- the pharmaceutical composition and cancer are as described above.
- the treatment method of the present application includes administering the pharmaceutical composition in a pharmaceutically effective amount to a subject suspected of having cancer.
- the object refers to all mammals including dogs, cows, horses, rabbits, mice, rats, chickens, and humans, but the mammals of the present application are not limited by the above examples.
- the pharmaceutical composition may be administered through parenteral, subcutaneous, intraperitoneal, intrapulmonary, and intranasal routes. For local treatment, it can be administered by any suitable method, including intralesional administration if necessary.
- Parenteral infusions include intramuscular, intravenous, intraarterial, intraperitoneal or subcutaneous administration.
- Preferred formulations are intravenous, subcutaneous, intradermal, intramuscular or drip formulations.
- a preferred dosage of the pharmaceutical composition of the present application may vary depending on the condition and body weight of the subject, the severity of the disease, the type of drug, the route and period of administration, and may be appropriately determined by a person skilled in the art.
- Another aspect of the present application provides a food composition for preventing or improving lung cancer, breast cancer or colorectal cancer, comprising the Leuconostoc mecenteroides strain of the present application, its culture, or a component derived therefrom as an active ingredient do.
- Another aspect of the present application is a health functional food for preventing or improving lung cancer, breast cancer or colorectal cancer, comprising the Leuconostoc mecenteroides strain of the present application, its culture, or a component derived therefrom as an active ingredient to provide.
- strains, cultures, derived components and cancers are as described above.
- the food composition may be in the form of a health functional food or food additive.
- health functional food refers to food manufactured and processed using raw materials or ingredients having functionality useful to the human body in accordance with the Health Functional Food Act (Article 3, Subparagraph 1), and "functional "” means to obtain useful effects for health purposes such as regulating nutrients for the structure and function of the human body or for physiological action (Article No. 2).
- the food composition may additionally contain food additives, and the suitability as a "food additive" is determined by the general rules and general test methods of the Food Additive Code approved by the Korea Food and Drug Administration, unless otherwise specified. judged according to the standard.
- Food Additives Codex examples include chemical synthetic products such as ketones, glycine, potassium citrate, nicotinic acid, and cinnamic acid, natural additives such as dark pigment, licorice extract, crystalline cellulose, and guar gum, L- and mixed preparations such as sodium glutamate preparations, noodle-added alkali preparations, preservative preparations, and tar color preparations.
- Foods containing the active ingredient of the present application include confectionery products such as bread, rice cakes, dried confections, candies, chocolates, chewing gum, jams, ice creams, ice creams, ice cream products such as ice cream powders; Dairy products such as milk, low-fat milk, lactose-degraded milk, processed milk, goat milk, fermented milk, butter milk, concentrated milk, milk cream, butter milk, natural cheese, processed cheese, powdered milk, and whey; meat products such as processed meat products, processed egg products, and hamburgers; fish meat products such as fish cakes, ham, sausages, and processed fish products such as bacon; noodles such as ramen, dried noodles, fresh noodles, fried noodles, luxury dried noodles, improved soft noodles, frozen noodles, and pasta; Beverages such as fruit drinks, vegetable drinks, carbonated drinks, soybean milk, lactobacillus drinks such as yogurt, and mixed drinks; seasonings such as soy sauce, soybean paste, gochujang, chunjang, chungkukjang,
- the food composition of the present application includes various nutrients, vitamins, electrolytes, flavors, colorants, pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohol , carbonation agents used in carbonated beverages, and the like.
- the food composition of the present application may include fruit flesh for preparing natural fruit juice, fruit juice beverages, and vegetable beverages. These components may be used independently or in combination.
- Another aspect of the present application provides a feed composition for preventing or improving lung cancer, breast cancer or colorectal cancer, comprising the Leuconostoc mecenteroides strain of the present application, its culture, or a component derived therefrom as an active ingredient do.
- strains, cultures, derived components and cancers are as described above.
- the feed composition may be in the form of a feed additive composition in addition to the feed composition.
- the composition When the composition is prepared as a feed additive, the composition may be 20 to 90% high concentration or may be prepared in powder or granular form.
- the feed additives are organic acids such as citric acid, fumaric acid, adipic acid, lactic acid, and malic acid, sodium phosphate, potassium phosphate, acid pyrophosphate, polyphosphate (polyphosphate), polyphenol, catechin, alpha-tocopherol, and rosemary. extract, vitamin C, green tea extract, licorice extract, chitosan, tannic acid, phytic acid, and the like, or any one or more natural antioxidants may be further included.
- the composition When prepared as a feed, the composition may be formulated in a conventional feed form, and may include common feed ingredients together.
- the feed and feed additives include grains such as milled or ground wheat, oats, barley, corn and rice; vegetable protein feeds such as those based on rape, soybean, and sunflower; animal protein feed such as blood meal, meat meal, bone meal and fish meal; It may further include sugar and dairy products, for example, dry ingredients composed of various powdered milk and whey powder, etc., and may further include nutritional supplements, digestion and absorption enhancers, growth promoters, and the like.
- the feed additive may be administered to animals alone or in combination with other feed additives in an edible carrier.
- the feed additives can be easily administered to animals as a top dressing, directly mixed with animal feed, or in an oral formulation separate from feed.
- a pharmaceutically acceptable edible carrier can be solid or liquid, for example corn starch, lactose, sucrose, soybean flakes, peanut oil, olive oil, sesame oil and propylene glycol.
- the feed additive may be a tablet, capsule, powder, troche or sugar-containing tablet or top dressing in a microdispersible form.
- the feed additive may be in the form of a gelatin soft capsule, or a syrup, suspension, emulsion, or solution formulation.
- the feed and feed additives may contain auxiliary agents, such as preservatives, stabilizers, wetting agents or emulsifying agents, solution accelerators, and the like.
- the feed additive may be used by adding it to an animal's feed by steeping, spraying or mixing.
- the feed or feed additive of the present application can be applied to a number of animal diets including mammals, poultry and fish.
- the mammal it can be used for pigs, cows, horses, sheep, rabbits, goats, rats, hamsters, and guinea pigs, which are rodents and laboratory rodents, as well as companion animals (eg, dogs and cats), and as the poultry, chickens, It can also be used for turkeys, ducks, geese, pheasants, and quails, and can be used for carp, crucian carp, and trout as the fish, but is not limited thereto.
- Leukonostok mecenteroides of the present application provides a pharmaceutical composition for the prevention or treatment of cancer comprising a culture thereof or a component derived therefrom as an active ingredient.
- Another aspect of the present application provides a method for preventing or treating cancer, comprising administering the pharmaceutical composition of the present application to a subject.
- Leuconostoc mesenteroides CJRS-10671 (Accession No. KCCM13059P) or Leuconostoc mesenteroides CJRS-10672 (Accession No. KCCM13060P) of the present application; its culture; Or it provides a food composition for preventing or improving cancer or inflammation, comprising a component derived therefrom as an active ingredient.
- Leuconostoc mesenteroides CJRS-10671 (Accession No. KCCM13059P) or Leuconostoc mesenteroides CJRS-10672 (Accession No. KCCM13060P) of the present application; its culture; Or it provides a health functional food for preventing or improving cancer or inflammation, containing a component derived therefrom as an active ingredient.
- Leuconostoc mesenteroides CJRS-10671 (Accession No. KCCM13059P) or Leuconostoc mesenteroides CJRS-10672 (Accession No. KCCM13060P) of the present application; its culture; Or it provides a feed composition for preventing or improving cancer or inflammation, comprising a component derived therefrom as an active ingredient.
- Leuconostoc mesenteroides CJRS-10671 (Accession No. KCCM13059P) or Leuconostoc mesenteroides CJRS-10672 (Accession No. KCCM13060P) of the present application; its culture; Or it provides a pharmaceutical composition for enhancing immunity, comprising a component derived therefrom as an active ingredient.
- Leuconostoc mesenteroides CJRS-10671 (Accession No. KCCM13059P) or Leuconostoc mesenteroides CJRS-10672 (Accession No. KCCM13060P) of the present application; its culture; Or it provides a food composition for enhancing immunity, comprising a component derived therefrom as an active ingredient.
- Leuconostoc mesenteroides CJRS-10671 (Accession No. KCCM13059P) or Leuconostoc mesenteroides CJRS-10672 (Accession No. KCCM13060P) of the present application; its culture; Or, it provides a health functional food for enhancing immunity, containing a component derived therefrom as an active ingredient.
- Leuconostoc mesenteroides CJRS-10671 (Accession No. KCCM13059P) or Leuconostoc mesenteroides CJRS-10672 (Accession No. KCCM13060P) of the present application; its culture; Or it provides a feed composition for enhancing immunity, comprising a component derived therefrom as an active ingredient.
- composition of the present application strains, cultures, derived components, cancer, inflammation and immune enhancement, etc. are as described in the other aspects.
- Example 1 Leuconostoc mesenteroides ( Leuconostoc mesenteroides ) Confirmation of sugar fermentation characteristics of the strain
- CJRS-10671 and CJRS-10672 strains of Leuconostoc mesenteroides isolated from kimchi were cultured using Difco's MRS liquid medium and Agar medium. Each medium was prepared according to the protocol and then sterilized at 121 ° C. for 15 minutes and used. Each strain was inoculated with 1% stock in MRS liquid medium 2 days before the experiment, incubated at 37°C for 20 hours, then inoculated with 2% in MRS liquid medium, and then cultured at 37°C for 20 hours. used
- the sugar fermentation characteristics of 49 carbohydrates were confirmed using the API 50 CHL kit (Biomerieux, France). Specifically, after washing the second subcultured strain with PBS (phosphate buffered saline), the strain was suspended in API 50 CHL medium based on McFarland standard 2.0, inoculated into a strip, and cultured at 37 ° C. for 24 hours. A yellow reaction using carbohydrates was read as a positive reaction, and a purple color was read as a negative reaction in which carbohydrates were not used.
- API 50 CHL kit Biomerieux, France
- antibiotic resistance evaluation was conducted to confirm the minimum inhibitory concentration (MIC) according to the EFSA antibiotic resistance evaluation guidelines.
- MIC minimum inhibitory concentration
- the guideline specifies the cut-off vlaues for 8 antibiotics.
- strains CJRS-10671 and CJRS-10672 met the criteria for 5 antibiotics, but exceeded the MIC criteria for some antibiotics, so antibiotic resistance was acquired as intrinsic resistance according to EFSA guidelines. Genetic analysis for resistance was performed, and the results are shown in Table 3 below. According to the EFSA guidelines, in the case of intrinsic resistance, it can be used because there is no possibility of external transfer of the antibiotic resistance gene to other bacteria.
- acid resistance and gallbladder resistance were evaluated to confirm suitability as an oral preparation. Specifically, the acid resistance test was performed by inoculating 1% of the second subcultured strain in a PBS solution corrected to pH 3.0 using 1N HCl, incubating at 37 ° C for 2 hours, and then comparing the initial viable cell count with the viable cell count after culture. .
- Tolerability was measured by inoculating 1% of the activated strain in a PBS solution containing 1% oxgall (Difco, USA) and comparing the number of viable cells after incubation at 37 ° C for 2 hours with the initial viable cell number.
- strain CJRS-10671 showed 95.7% acid resistance and 136.6% tolerance based on 100% initial viable count
- strain CJRS-10672 showed 120.6 based on 100% initial viable count. % acid resistance and 67.9% acid resistance.
- HT-29 cell line Korean Cell Line Bank, KCLB; Seoul, Korea
- DMEM Dulbecco's Modified Eagle's minimal essential medium
- the HT-29 cell line was seeded with 1.0X10 5 cells/24 well to form a monolayer of about 80%, and then washed twice with PBS to remove antibiotics contained in DMEM.
- the degree of intestinal adhesion was expressed as the number of strain CFU attached per 100 HT-29 cell lines, and as a control, Bifidobacterium bifidum ( Bifidobacterium bifidum ), Bifidobacterium infantis ( B. infantis ), Bifidobacterium lac This ( B. lactis ) ATCC type strain was used.
- the intestinal adhesion capacity was about 217 ⁇ 21 bacteria/100 cells, equivalent to or better than that of the control strain (FIG. 3).
- Example 7 Immune-enhancing cytokine secretion confirmation by strain
- IL-6 secretion known as an immune-enhancing cytokine
- CJRS-10671 and CJRS-10672 of Example 1 As immunocytes, mouse macrophage cell line (Raw 264.7) and human monocytes (THP-1) were used. One week before entering the experiment, the Raw 264.7 cell line was subcultured and maintained in DMEM medium containing 10% FBS and 1% Antibiotic-antimycotic, and seeded in a flat 96-well plate at 6x10 4 cells/well one day before the experiment.
- the THP-1 cell line was subcultured and maintained in RPMI medium containing 10% FBS, 1% penicillin-streptomycin (PS) and 2-mercaptoethanol (2-ME) 0.05 mM, and 8x10 4 cells 2 days before the experiment.
- RPMI medium containing 10% FBS, 1% penicillin-streptomycin (PS) and 2-mercaptoethanol (2-ME) 0.05 mM, and 8x10 4 cells 2 days before the experiment.
- PMA Phorbol 12-myristate 13-acetate
- CJRS-10671 and CJRS-10672 increased IL-6 secretion when co-cultured with mouse or human-derived macrophages (FIG. 4).
- CJRS-10671 or CJRS-10672 induces the secretion of IL-12p70, known as an immune-enhancing cytokine, in human PBMCs was measured.
- Human PBMCs were seeded in 96 well plates at 2x10 5 cells/well. Then, when co-cultivating with CJRS-10671 and CJRS-10672, the medium containing 10% FBS without antibiotics was used. Then treated with immune cells at a ratio of 1:10. As a result of obtaining the supernatant after 24 hours of culture, it was confirmed that CJRS-10671 and CJRS-10672 increased IL-12p70 secretion when co-cultured with human PBMC (FIG. 5).
- IFN ⁇ Interferon-gamma
- CD8 T cells which are cytotoxic T cells, greatly affects anticancer efficacy.
- CD8 + IFN ⁇ + was confirmed using mouse splenocytes and human PBMC to confirm the IFN ⁇ secretion ability of cytotoxic T cells by CJRS-10671 and CJRS-10672 strains.
- HBSS Human Brain Staline
- collagenase IV was inserted into the mouse spleen tissue with a syringe to allow the cells to flow out. After repeating this several times, the remaining tissue was cut into small pieces using a syringe and incubated at 37° C. for 25 minutes. It was further incubated for 5 minutes at 37° C. with 0.5M EDTA added. After mixing the cells using a Pasteur pipette, the cells were filtered through a cell strainer. After centrifugation at 1500 rpm for 3 minutes, red blood cells were removed using 1x RBC lysis buffer, and splenocytes were suspended in a new medium and used for the experiment.
- Human PBMCs were purchased from stemcell technologies and stored in nitrogen tanks after receipt until use in experiments. On the day of the experiment, the stock was taken out of the nitrogen tank and melted in a constant temperature water bath. After putting RPMI1640 medium supplemented with 10% FBS and centrifuging at 1500 rpm for 5 minutes, the PBMC were suspended in a new medium and used for the experiment.
- a stimulator of T cells is required, so 0.1 ⁇ g/ml of anti-CD3 antibody was diluted in PBS 1 day before co-culture with the strain, and the concentration was 0.1 ⁇ g/ml in a flat 96-well plate. were coated in a volume of 100 ⁇ l per well. On the day of co-culture, the coated plate was prepared by washing twice with PBS, mouse splenocytes were isolated according to the protocol, and 5x10 5 cells/well were added to a 96-well plate coated with 1 ⁇ g/ml of purified anti-CD28 antibody.
- CJRS-10671 and CJRS-10672 strains were co-cultured with splenocytes at a ratio of 1:10 using an antibiotic-free culture medium. After 3 days of co-culture, brefeldin A was added, golgi stop was performed for 3-4 hours, and then markers to be identified were stained using BD transcription factor buffer set and fluorescent antibody to prepare analysis samples. Analysis samples were analyzed using BD Lyric (flow cytometer) and Flowjo programs, and the results were confirmed.
- Human PBMCs were seeded at 2 x 10 5 cells/well, and co-culture was performed in the same manner as in Example 7-2.
- CJRS-10671 and CJRS-10672 increased the IFN ⁇ secretion ability of CD8 T cells in mouse splenocytes and human PBMC (FIG. 6).
- lung cancer cell line LLC1 Lewis lung carcinoma, LL/2, LLC1
- colorectal cancer cell line MC38 Murine Carcinoma-38 cells were used.
- LLC1 and MC38 cell lines were cultured and maintained in DMEM medium containing 10% FBS and 1% Anti-anti. LLC1 and MC38 cell lines were seeded in a 6-well plate at 2.4x10 5 cells/well and 1.2x10 5 cells/well, respectively.
- CJRS-10671 and CJRS-10672 strains were added at ratios of cancer cell lines: strains of 1:10, 1:100, and 1:1000. After co-cultivation for 24 hours, the cells were removed using trypsin-EDTA, washed with 1x PBS, and 5 ml of ice-cold 75% EtOH was added while only the cells were left, and stored overnight at -20 ° C. Thereafter, Ki67 and PI fluorescence staining was performed, and cell cycle results were analyzed using BD Lyric (flow cytometer) and Flowjo programs. A group not treated with CJRS-10671 and CJRS-10672 strains (strain untreated group) was used as a control group.
- CJRS-10671 and CJRS-10672 strains of Example 1 were seeded in 6-well plates at 2.4x10 5 cells/well and 1.2x10 5 cells/well, respectively. . After 24 hours, the medium was replaced with a medium containing 0.5% FBS, followed by serum starvation for 24 hours.
- CJRS-10671 and CJRS-10672 were treated at a cancer cell line:strain ratio of 1:10, 1:100, and 1:1000, and after 24 hours of co-culture, the cells were detached using trypsin-EDTA, washed with 1x PBS, and killed.
- mice were subcutaneously injected with LLC1 cell line 4 x 10 5 cells/mouse. After tumor cell injection, when the tumor size reached about 30-50 mm 3 , the mice were divided into the following groups: negative control group (no treatment after tumor cell injection), CJRS-10671 or CJRS-10672 sample treated group, and immune control group. A group treated with checkpoint inhibitor anti-PD-1 (positive control group) and a group treated with CJRS-10671 or CJRS-10672 samples and anti-PD-1 in combination.
- CJRS-10671 or CJRS-10672 samples were diluted in 100 ⁇ l PBS to 10 9 CFU per animal and administered a total of 10 times for 10 days, and anti-PD-1 (10 mg/kg, BioXCell) was intraperitoneally administered once every 2 days. did The size of the tumor was measured with a caliper three times a week, and the mouse was sacrificed on the day after the end of administration, the tumor weight was measured, and blood and organs were obtained and analyzed.
- splenocytes were separated from the spleen tissue of each group and seeded in a round-bottom 96-well plate at 10 6 cells/well. After stimulation of splenocytes with PMA/Ionomycin, which stimulates all immune cells, for 3-4 hours, surface marker staining and intracellular cytokine staining (ICS) were performed, followed by FACS to measure the amount of IFN ⁇ secreted by CD8 T cells. quantity was confirmed.
- PMA/Ionomycin which stimulates all immune cells
- CD8 T cell function the same isolated splenocytes were stimulated for 1 day with CD3/CD28 (anti-CD3 antibody 2 ⁇ g/ml, anti-CD28 antibody 2 ⁇ g/ml) that stimulates T cells, followed by surface marker staining. and ICS were performed, and the amount of IFN ⁇ secreted by CD8 T cells was confirmed by FACS.
- CD3/CD28 anti-CD3 antibody 2 ⁇ g/ml, anti-CD28 antibody 2 ⁇ g/ml
- TILs tumor-infiltration lymphocytes
- CD3/CD28 anti-CD3 antibody 2 ⁇ g/ml, anti-CD3 antibody 2 ⁇ g/ml, anti- After 1-day stimulation with CD28 antibody (2 ⁇ g/ml)
- surface marker staining and ICS were performed, and the amount of IFN ⁇ secreted by CD8 T cells was confirmed by FACS.
- both the CJRS-10671 and anti-PD-1 combination treatment group and the CJRS-10672 and anti-PD-1 combination treatment group increased the amount of IFN ⁇ secreted by CD8 T cells during T cell stimulation (FIG. 13).
- splenocytes were isolated from the spleen tissue of each group, and surface marker staining was performed using a fluorescent antibody to confirm changes in immune cells and immunosuppressive cells.
- the fluorescent markers for each immune cell were used as follows: M1 (CD11b + F4/80 + CD86 + ), M2 (CD11b + F4/80 + CD206 + ), DC (IA-IE + CD11b + CD11c + ), B cells (CD3 - B220 + ), NK cells (CD3 - NK1.1 + ), NKT cells (CD3 + NK1.1 + ), Treg (CD4 + CD25 + Foxp3 + ). Analysis Samples were analyzed with BD Lyric (flow cytometer) and Flowjo programs, and the results were confirmed by % and #.
- mice were subcutaneously injected with 3 x 10 5 cells/mouse of the 4T1 cell line.
- the mice were divided into the following groups: negative control group (no treatment after tumor cell injection), CJRS-10672 sample treated group, and immune checkpoint inhibitor A group treated with anti-PD-1 (positive control group) and a group treated with CJRS-10672 samples and anti-PD-1 in combination.
- CJRS-10672 samples were diluted in 100 ⁇ l PBS to 10 9 CFU per animal and administered a total of 10 times for 10 days, and anti-PD-1 (10 mg/kg, BioXCell) was intraperitoneally administered once every 2 days.
- the size of the tumor was measured with a caliper three times a week, and the mouse was sacrificed on the day after the end of administration, the tumor weight was measured, and blood and organs were obtained and analyzed.
- Example 10-4 the number of MDSC, which are immunosuppressive cells, among the obtained spleen-derived cells was confirmed in the same manner as in Example 10-4.
- CJRS-10672 reduced the size of breast cancer compared to the negative control group or the anti-PD-1 treated group. True individuals were identified (FIG. 17).
- the CJRS-10671 and CJRS-10672 strains were deposited with the Korean Culture Center of Microorganisms (KCCM), an international depository institution under the Budapest Treaty, on October 19, 2021, respectively, and were given accession numbers KCCM13059P and KCCM13060P.
- KCCM Korean Culture Center of Microorganisms
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Polymers & Plastics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Nutrition Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Physiology (AREA)
- Animal Husbandry (AREA)
- Zoology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
No. | Type of test | CJRS-10671 | CJRS-10672 | No. | Type of test | CJRS-10671 | CJRS-10672 |
0 | Control | - | - | 25 | Esculin | ++ | ++ |
1 | Glycerol | - | - | 26 | Salicin | ++ | - |
2 | Erythritol | - | - | 27 | D-cellibiose | ++ | - |
3 | D-Arabinose | - | - | 28 | D-Maltose | ++ | ++ |
4 | L-Arabinose | ++ | ++ | 29 | D-Lactose | - | - |
5 | D-Ribose | ++ | ++ | 30 | D-Melibiose | ++ | ++ |
6 | D-Xylose | ++ | ++ | 31 | D-Saccharose (sucrose) | ++ | ++ |
7 | L-Xylose | - | - | 32 | D-trehalose | ++ | ++ |
8 | D-Adonitol | - | - | 33 | Inullin | - | - |
9 | Methyl-β-D-xylopyranoside | - | - | 34 | D-Melezitose | - | - |
10 | D-Galactose | - | - | 35 | D-Raffinose | ++ | ++ |
11 | D-glucose | ++ | ++ | 36 | Amidon | - | - |
12 | D-fructose | ++ | ++ | 37 | Glycogen | - | - |
13 | D-Mannose | ++ | ++ | 38 | Xylitol | - | - |
14 | L-Sorbose | - | - | 39 | Gentibiose | ++ | - |
15 | L-Rhamnose | - | - | 40 | D-Turanose | ++ | - |
16 | Dulcitol | - | - | 41 | D-Lyxose | - | - |
17 | Inositol | - | - | 42 | D-Tagatose | - | - |
18 | D-Manitol | + | + | 43 | D-Fucose | - | - |
19 | D-Sorbitol | + | - | 44 | L-Fucose | - | - |
20 | Methyl-a-D-Mannopyranoside | - | - | 45 | D-Arabitol | - | - |
21 | Methyl-a-D-Glucopyranoside | ++ | ++ | 46 | L-Arabitol | - | - |
22 | N-Acetyl Glucosamine | ++ | ++ | 47 | potassium glucoNaTe | + | - |
23 | Amygdalin | + | - | 48 | potassium 2-ketogluconate | - | + |
24 | Arbutine | + | + | 49 | potassium 5-Ketoglyconate | - | - |
(++): positive reaction (yellow), no. 25 (black), (+): weak reaction, (-): negative reaction (purple) |
No. | Enzyme | CJRS-10671 | CJRS-10672 |
1 | Control | ||
2 | Alkaline phosphatase | 0 | 0 |
3 | Esterase (c4) | 1 | 1 |
4 | Esterase lipase (C8) | 0 | 0 |
5 | Lipase (c14) | 0 | 0 |
6 | Leucine arylamidase | 1 | 1 |
7 | Valine arylamidase | 0 | 0 |
8 | Cystine arylamidase | 0 | 0 |
9 | Trypsin | 0 | 0 |
10 | α-chymotrypsin | 0 | 0 |
11 | Acid phosphatase | 0.5 | 0.5 |
12 | Naphthol-AS-BO-phosphohydrolase | 1 | 1 |
13 | α-galactosidase | 0.5 | 0 |
14 | β-galactosidase | 4 | 1 |
15 | β-glucuronidase | 0 | 0 |
16 | α-glucosidase | 5 | 2 |
17 | β-glucosidase | 5 | 5 |
18 | N-acetyl-β-glucosamidase | 0 | 0 |
19 | α-mannosidase | 0 | 0 |
20 | α-fucosidase | 0 | 0 |
Antibiotics | Leuconostoc mesenteroides | |||
Cut- off values (mg/L) |
CJRS-10671 | CJRS-10672 | Susceptibility | |
Ampicillin | 4 | 0.5 | 0.5 | susceptible |
Vancomycin | N.R. | N.R. | N.R. | N.R. |
Gentamycin | 16 | 8 | 16 | susceptible |
Kanamycin | 16 | 128 | 512 | resistance |
Streptomycin | 64 | 128 | 128 | Moderate resistance |
Erythromycin | 1 | 0.125 | 0.125 | susceptible |
Clindamycin | 1 | 0.03125 | 0.0625 | susceptible |
Tylosin | N.R. | N.R. | N.R. | N.R. |
Tetracycline | 8 | 2 | 1 | susceptible |
Chloramphenicol | 4 | 32 | 32 | Moderate resistance* Intrinsic resistance (AB Flσrez, 2005) |
Bacteria | Acid tolerance (%) | Bile salts tolerance (%) |
CJRS-10671 | 95.7 ± 12.2 | 136.6 ± 24.6 |
CJRS-10672 | 120.6 ± 31.1 | 67.9 ± 3.3 |
Claims (18)
- 류코노스톡 메센테로이데스(Leuconostoc mesenteroides) 균주, 이의 배양물 또는 이로부터 유래하는 성분을 유효성분으로 포함하는, 폐암 또는 유방암의 예방 또는 치료용 약학적 조성물.
- 류코노스톡 메센테로이데스 CJRS-10671(수탁번호 KCCM13059P) 또는 류코노스톡 메센테로이데스 CJRS-10672(수탁번호 KCCM13060P); 이의 배양물; 또는 이로부터 유래하는 성분을 유효성분으로 포함하고, 항암제와 병용 투여되는, 대장암의 예방 또는 치료용 약학적 조성물.
- 제1항에 있어서, 상기 류코노스톡 메센테로이데스 균주는 류코노스톡 메센테로이데스 CJRS-10671(수탁번호 KCCM13059P) 또는 류코노스톡 메센테로이데스 CJRS-10672(수탁번호 KCCM13060P) 중 선택되는 어느 하나 이상인 것인, 조성물.
- 제1항에 있어서, 상기 조성물은 항암제와 병용 투여되는 것인, 조성물.
- 제2항 또는 제4항에 있어서, 상기 항암제는 면역 항암제인 것인, 조성물.
- 제5항에 있어서, 상기 면역 항암제는 항-PD-1(programmed cell death protein 1,), 항-PD-L1(programmed cell death-ligand 1), CTLA4(Cytotoxic T Lymphocyte associated Antigen 4), CTLA4/B7-1/B7-2 상호작용억제제 및 CD47/SIRP(Cluster of Differentiation 47/Signal-regulatory protein) 상호작용억제제, 항-Tim3(T-cell immunoglobulin and mucin domain 3) 및 항-LAG3(Lymphocyte Activating 3)로 이루어지는 군으로부터 선택되는 어느 하나 이상인 것인, 조성물.
- 제1항 또는 제2항에 있어서, 상기 조성물의 투여는 항암 요법과 병용되는 것인, 조성물.
- 제7항에 있어서, 상기 항암 요법은 방사선요법(radiotherapy), 네오아쥬번트요법(neoadjuvant therapy), 화학요법(chemotherapy), 표적요법(targeted therapy) 및 광역학 요법(Photodynamic therapy)으로 이루어지는 군으로부터 선택되는 어느 하나 이상인 것인, 조성물.
- 제1항 또는 제2항에 있어서, 상기 조성물은 복강 내 투여, 정맥 내 투여, 근육 내 투여, 피하 투여, 피 내 투여, 경구 투여, 국소 투여, 비 내 투여, 폐 내 투여 및 직장 내 투여로 이루어지는 군으로부터 선택되는 어느 하나 이상의 투여방법으로 투여되는 것인, 조성물.
- 류코노스톡 메센테로이데스 균주, 이의 배양물 또는 이로부터 유래하는 성분을 유효성분으로 포함하는, 폐암, 유방암 또는 대장암의 예방 또는 개선용 식품 조성물.
- 류코노스톡 메센테로이데스 균주, 이의 배양물 또는 이로부터 유래하는 성분을 유효성분으로 포함하는, 폐암, 유방암 또는 대장암의 예방 또는 개선용 건강기능식품.
- 류코노스톡 메센테로이데스 균주, 이의 배양물 또는 이로부터 유래하는 성분을 유효성분으로 포함하는, 폐암, 유방암 또는 대장암의 예방 또는 개선용 사료 조성물.
- 류코노스톡 메센테로이데스 CJRS-10671(수탁번호 KCCM13059P) 또는 류코노스톡 메센테로이데스 CJRS-10672(수탁번호 KCCM13060P); 이의 배양물; 또는 이로부터 유래하는 성분을 유효성분으로 포함하는, 암 또는 염증 예방 또는 개선용 식품 조성물.
- 류코노스톡 메센테로이데스 CJRS-10671(수탁번호 KCCM13059P) 또는 류코노스톡 메센테로이데스 CJRS-10672(수탁번호 KCCM13060P); 이의 배양물; 또는 이로부터 유래하는 성분을 유효성분으로 포함하는, 암 또는 염증 예방 또는 개선용 건강기능식품.
- 류코노스톡 메센테로이데스 CJRS-10671(수탁번호 KCCM13059P) 또는 류코노스톡 메센테로이데스 CJRS-10672(수탁번호 KCCM13060P); 이의 배양물; 또는 이로부터 유래하는 성분을 유효성분으로 포함하는, 암 또는 염증 예방 또는 개선용 사료 조성물.
- 류코노스톡 메센테로이데스 CJRS-10671(수탁번호 KCCM13059P) 또는 류코노스톡 메센테로이데스 CJRS-10672(수탁번호 KCCM13060P); 이의 배양물; 또는 이로부터 유래하는 성분을 유효성분으로 포함하는, 면역 증강용 식품 조성물.
- 류코노스톡 메센테로이데스 CJRS-10671(수탁번호 KCCM13059P) 또는 류코노스톡 메센테로이데스 CJRS-10672(수탁번호 KCCM13060P); 이의 배양물; 또는 이로부터 유래하는 성분을 유효성분으로 포함하는, 면역 증강용 건강기능식품.
- 류코노스톡 메센테로이데스 CJRS-10671(수탁번호 KCCM13059P) 또는 류코노스톡 메센테로이데스 CJRS-10672(수탁번호 KCCM13060P); 이의 배양물; 또는 이로부터 유래하는 성분을 유효성분으로 포함하는, 면역 증강용 사료 조성물.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP22896101.7A EP4427757A1 (en) | 2021-11-17 | 2022-11-17 | Composition for preventing or treating cancer or inflammation comprising novel leuconostoc mesenteroides strain, and method for preventing or treating cancer or inflammation using same |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020210158921A KR20230072316A (ko) | 2021-11-17 | 2021-11-17 | 신규 류코노스톡 메센테로이데스 균주를 포함하는 암 또는 염증 예방 또는 치료용 조성물 및 이를 이용한 암 또는 염증의 예방 또는 치료 방법 |
KR10-2021-0158921 | 2021-11-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023090903A1 true WO2023090903A1 (ko) | 2023-05-25 |
Family
ID=86397438
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2022/018223 WO2023090903A1 (ko) | 2021-11-17 | 2022-11-17 | 신규 류코노스톡 메센테로이데스 균주를 포함하는 암 또는 염증 예방 또는 치료용 조성물 및 이를 이용한 암 또는 염증의 예방 또는 치료 방법 |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP4427757A1 (ko) |
KR (1) | KR20230072316A (ko) |
WO (1) | WO2023090903A1 (ko) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20160039095A (ko) * | 2014-09-30 | 2016-04-08 | 한국식품연구원 | 류코노스톡 메센테로이데스 wikim19 및 이를 포함하는 조성물 |
KR101909999B1 (ko) * | 2017-07-21 | 2018-10-19 | 건국대학교 산학협력단 | 신규 류코노스톡 메센테로이데스 균주 및 이를 이용한 암 예방 또는 치료용 조성물 |
WO2019169179A1 (en) * | 2018-02-28 | 2019-09-06 | Shafer Kim | Augmenting efficacy of cancer therapies using probiotic based compositions |
KR20210112980A (ko) * | 2020-03-05 | 2021-09-15 | 주식회사 리스큐어바이오사이언시스 | 류코노스톡 속 균주를 유효성분으로 포함하는 암의 예방 또는 치료용 약학 조성물 |
WO2022103138A1 (ko) | 2020-11-13 | 2022-05-19 | 주식회사 비피도 | 비피도박테리움 롱검 rapo (kctc13773bp)를 포함하는 암 예방 또는 치료용 조성물 |
-
2021
- 2021-11-17 KR KR1020210158921A patent/KR20230072316A/ko unknown
-
2022
- 2022-11-17 WO PCT/KR2022/018223 patent/WO2023090903A1/ko active Application Filing
- 2022-11-17 EP EP22896101.7A patent/EP4427757A1/en active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20160039095A (ko) * | 2014-09-30 | 2016-04-08 | 한국식품연구원 | 류코노스톡 메센테로이데스 wikim19 및 이를 포함하는 조성물 |
KR101909999B1 (ko) * | 2017-07-21 | 2018-10-19 | 건국대학교 산학협력단 | 신규 류코노스톡 메센테로이데스 균주 및 이를 이용한 암 예방 또는 치료용 조성물 |
WO2019169179A1 (en) * | 2018-02-28 | 2019-09-06 | Shafer Kim | Augmenting efficacy of cancer therapies using probiotic based compositions |
KR20210112980A (ko) * | 2020-03-05 | 2021-09-15 | 주식회사 리스큐어바이오사이언시스 | 류코노스톡 속 균주를 유효성분으로 포함하는 암의 예방 또는 치료용 약학 조성물 |
WO2022103138A1 (ko) | 2020-11-13 | 2022-05-19 | 주식회사 비피도 | 비피도박테리움 롱검 rapo (kctc13773bp)를 포함하는 암 예방 또는 치료용 조성물 |
Non-Patent Citations (2)
Title |
---|
FUJINO FUKUYO, NISHIO MISA, TSUDUKI MASAO, WATANABE TAKUMI, HATANAKA MIHO, HAYASHI KYOKO, KITADA YOSHIMI: "Immune system enhancement properties of a culture substance containing kudzu dextrin in the lactic acid bacteria Leuconostoc mesenteroides found in the kudzu vine", JAPANESE JOURNAL OF FOOD CHEMISTRY AND SAFETY, vol. 27, no. 1, 1 January 2020 (2020-01-01), pages 22 - 27, XP093068390 * |
MIN ARIM, KWON BO-EUN, KIM HYUNJEONG, PARK HYUNKYUNG, LEE JIYOUNG, PYO KYOUNG-HO, CHO BYOUNG CHUL: "Abstract 3527: Novel bacteria strains, CJRS-10671 and CJRS-10672, enhance anti-tumor efficacy in LLC1 syngeneic model and humanized PDX mice model", CANCER RESEARCH, vol. 82, no. 12_Supplement, 15 June 2022 (2022-06-15), XP093068095, DOI: 10.1158/1538-7445.AM2022-3527 * |
Also Published As
Publication number | Publication date |
---|---|
KR20230072316A (ko) | 2023-05-24 |
TW202337479A (zh) | 2023-10-01 |
EP4427757A1 (en) | 2024-09-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2019216649A1 (ko) | 암을 예방 또는 치료하는 효과를 갖는 신규한 균주 | |
WO2011010770A1 (ko) | 신규한 락토바실러스 플란타룸 및 이를 포함하는 조성물 | |
WO2015122717A1 (ko) | 비만 억제 효능을 갖는 신규 유산균 및 이의 용도 | |
WO2021060945A1 (ko) | 암 치료를 위한 절대혐기성 인체 장내미생물 및 이의 용도 | |
WO2020075949A1 (ko) | 신규한 락토바실러스 플란타룸 균주 atg-k2, atg-k6 또는 atg-k8, 이를 포함하는 질염의 예방 또는 치료용 조성물 | |
WO2022203303A1 (ko) | 락토바실러스 플란타럼 gb104 균주 및 이를 포함하는 암 예방 또는 치료용 조성물 | |
WO2020013669A1 (ko) | 항바이러스 효과 및 면역조절 효능을 가지는 락토바실러스 플란타럼 cjlp475 균주 및 이를 포함하는 조성물 | |
WO2022045636A1 (ko) | 항암 활성을 갖는 락토바실러스 플란타룸 미생물, 그를 포함하는 조성물 및 그를 이용한 암 예방 또는 치료 방법 | |
WO2020013670A1 (ko) | 락토바실러스 플란타럼 cjlp475 균주 및 락토바실러스 플란타럼 cjlp17 균주를 포함하는 조성물 및 이의 용도 | |
WO2023090903A1 (ko) | 신규 류코노스톡 메센테로이데스 균주를 포함하는 암 또는 염증 예방 또는 치료용 조성물 및 이를 이용한 암 또는 염증의 예방 또는 치료 방법 | |
WO2023090900A1 (ko) | 신규 류코노스톡 메센테로이데스 균주 | |
WO2023068855A1 (ko) | 항암 활성을 갖는 베일로넬라 파르불라 균주를 이용한 암의 완화, 예방 또는 치료용 조성물 | |
WO2014042392A1 (ko) | 메트포민을 이용한 루프스를 포함하는 면역질환의 예방 또는 치료용 조성물 | |
WO2020013672A1 (ko) | 락토바실러스 플란타럼 cjlp475 균주 및 락토바실러스 플란타럼 cjlp243 균주를 포함하는 조성물 및 이의 용도 | |
WO2023113541A1 (en) | Pharmaceutical composition for preventing or treating cancer or inflammatory disease | |
WO2018147612A1 (ko) | 암의 전이 억제 및 치료용 조성물 | |
WO2022045637A1 (ko) | 항종양 세균 균주, 및 이를 이용한 조성물 및 방법 | |
TWI847370B (zh) | 用以預防或治療癌症或發炎的包含新穎腸膜明串珠菌菌株之組成物及使用其預防或治療癌症或發炎的方法 | |
WO2019198982A1 (ko) | 구꼬아민 a 및 구꼬아민 b를 유효성분으로 함유하는 골격근 위축 예방 또는 개선용 조성물 | |
TWI847369B (zh) | 新穎腸膜明串珠菌菌株 | |
WO2024029958A1 (ko) | 면역조절 기능이 강화된 유산균 사균체 생산 방법 | |
WO2022139530A1 (ko) | 락토바실러스 사케아이 유래 세포밖 소포체를 유효성분으로 포함하는 자가면역질환의 개선, 예방 또는 치료용 조성물 | |
WO2022139531A1 (ko) | 류코노스톡 시트리움 유래 세포밖 소포체를 유효성분으로 포함하는 지방간 개선, 예방 또는 치료용 조성물 | |
WO2013151363A1 (ko) | 신규 분리한 바실러스 리체니포미스 및 이를 이용한 프로바이오틱스 | |
WO2024063545A1 (ko) | 락토바실러스 플란타룸 균주를 포함하는 장내 대사산물 조성의 개선을 위한 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22896101 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2024529694 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2022896101 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2022896101 Country of ref document: EP Effective date: 20240604 |